In the novel WHO classification 2008, the classification of aggressive B-cell lymphoma has been revised for several categories with the aim to define "clean" entities. Within large B-cell lymphoma, a few distinct clinico-pathological entities have been recognized with more clinically defined entities than pathologically defined ones. The majority of known morphological variations were not considered to merit more than classification as a variant of DLBCL, not otherwise specified. Specifically, a biological subgrouping of DLBCL on the basis of molecular (activated B-cell versus germinal center B-cell) or immunophenotypic (CD5+) features was felt to be too immature to include at this stage. The role of EBV in aggressive B-cell lymphoma has been explored in more depth with the recognition of several novel and re-defined clinico-pathological entities. Also, in these diseases, clinical definitions play a very dominant role in the WHO classification 2008. © Springer-Verlag 2009.
CITATION STYLE
Balague Ponz, O., Ott, G., Hasserjian, R. P., Elenitoba-Johnson, K. S. J., de Leval, L., & de Jong, D. (2009). Commentary on the WHO classification of tumors of lymphoid tissues (2008): Aggressive B-cell lymphomas. Journal of Hematopathology, 2(2), 83–87. https://doi.org/10.1007/s12308-009-0038-8
Mendeley helps you to discover research relevant for your work.